Atay Oguzhan sold $1.6M of BLLN

Atay Oguzhan (Chairman and CEO) sold 12,500 shares of BillionToOne, Inc. (BLLN) at an average of $126.10 ($125.43–$128.23, $1.58M total) across 4 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Jul 13, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or whether the company has other concurrent disclosures, but this specific filing alone does not change fundamentals.

02

Market read

A $1.58M insider sale under a 10b5-1 plan is disclosed; expect at most a modest, short-lived sentiment effect absent other catalysts.

03

What to watch

The filing shows the insider ended with 0 shares, which can be read as a stronger sentiment signal than typical partial sales, even if the plan is pre-arranged.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed July 13, covering sales executed July 9

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

SEC Form 4 shows BLLN CEO/Chairman Atay Oguzhan sold 12,500 shares in open-market trades totaling about $1.58M, leaving 0 shares.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include new company fundamentals, guidance, or operational/regulatory developments. The presence of a pre-arranged 10b5-1 plan further reduces the likelihood of a strong directional signal.

Market effects

Minimal. Insider sales in a single biotech/health-tech name typically do not reset sector expectations without accompanying fundamentals.

None indicated.

None indicated.

Counterpoint

The sale is explicitly under a pre-arranged 10b5-1 plan, so it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Atay Oguzhan

    Chairman and CEO who sold shares in open-market trades under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.